Marshall Wace
QNCX icon

Marshall Wace’s Quince Therapeutics QNCX Stock Holding History

Marshall Wace’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,559
Closed -$1.71M – 3593
2025
Q4 		$1.71M Buy
2,559
+1,509
+144% +$759K ﹤0.01% 1652
2025
Q3 		$342K Buy
+1,050
New +$350K ﹤0.01% 2376
2022
Q3 		– Sell
-82
Closed -$36K – 3712
2022
Q2 		$36K Buy
+82
New +$58K ﹤0.01% 3342
2021
Q4 		– Sell
-304
Closed -$5.56M – 4208
2021
Q3 		$5.56M Buy
304
+111
+58% +$1.77M 0.02% 880
2021
Q2 		$2.05M Buy
+193
New +$1.62M 0.01% 1398
2021
Q1 		– Sell
-178
Closed -$987K – 2789
2020
Q4 		$987K Sell
178
-16
-8% -$142K 0.01% 1219
2020
Q3 		$1.94M Buy
194
+115
+146% +$1.05M 0.01% 815
2020
Q2 		$735K Buy
79
+63
+394% +$577K 0.01% 1087
2020
Q1 		$150K Buy
+16
New +$158K ﹤0.01% 1242

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace's QNCX Position: Q1 2026 in Review

Marshall Wace sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 2,559 shares — an estimated $1.71M sold.

Marshall Wace first reported a position in QNCX in Q1 2020 and held it in 9 quarters. The position peaked at $5.56M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Marshall Wace reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Marshall Wace sold 2,559 Quince Therapeutics shares in Q1 2026, an estimated $1.71M.
  • Marshall Wace first reported a position in Quince Therapeutics in Q1 2020 and held it in 9 quarters.
  • Marshall Wace's Quince Therapeutics position peaked at $5.56M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.